Brand Reference: Lozol
| Metric | Verified Benchmark | Source |
|---|---|---|
| Indapamide RxNorm Concept ID | 5764 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0850 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $35.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.30 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $7.60 / mo | 12 Zero-PHI Verified Patient Logs |
Combines mild proximal/distal tubular natriuresis with direct vascular smooth-muscle prostacyclin synthesis and transmembrane calcium-current attenuation, lowering arterial stiffness at 1.25 mg with minimal lipid or glycemic perturbation.
For self-pay patients filling Indapamide (NDC 00378-0571-01), direct wholesale and telehealth fulfillment drops monthly spend from $35.00 retail to $6.30 (82% savings against a $0.0850 CMS pharmacy acquisition baseline).
Clinical clearance of Indapamide (Metabolically Neutral Indoline Thiazide-Like Vasodilator Diuretic) relies on extensive hepatic cyp3a4/cytosolic metabolism; <7% unchanged in urine with a 14–18 hours biphasic half-life; patients absorbing at 93% oral bioavailability typically observe target onset around 1–2 hours peak plasma.
FDA clinical labeling for Indapamide restricts administration in anuria; severe hepatic encephalopathy; hypokalemia across 1.25 mg PO QAM, 2.5 mg PO QAM, with self-reported patient tracking dominated by mild electrolyte shift (8% of reports), lightheadedness (5% of reports).
Across 12 verified cash-pay logs, Indapamide achieves a 86.10% Worth-It rating with out-of-pocket spend averaging $7.60/mo versus $35.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 1.25 mg PO QAM for Indapamide; monthly out-of-pocket dropped to $5.54 compared with $35.00 retail.
Completed 10 weeks on Indapamide (2.5 mg PO QAM). Zero notable side effects on steady dosing.
Consistent biomarker response on 1.25 mg PO QAM Indapamide sourced via TeleMed ($7.31/mo cash pay without insurance prior authorization).